Delayed hypersensitivity reaction resulting in maculopapular-type eruption due to entecavir in the treatment of chronic hepatitis B

被引:16
作者
Kim, Jeong Tae [1 ,2 ]
Jeong, Hye Won [1 ,2 ]
Choi, Ki Hwa [2 ,3 ]
Yoon, Tae Young [2 ,3 ]
Sung, Nohyun [2 ,4 ]
Choi, Young Ki [2 ,5 ]
Kim, Eun Ha [2 ,5 ]
Chae, Hee Bok [1 ,2 ]
机构
[1] Chungbuk Natl Univ, Coll Med, Dept Internal Med, Cheongju 361711, South Korea
[2] Chungbuk Natl Univ, Med Res Inst, Cheongju 361711, South Korea
[3] Chungbuk Natl Univ, Coll Med, Dept Dermatol, Cheongju 361711, South Korea
[4] Chungbuk Natl Univ, Coll Med, Dept Pathol, Cheongju 361711, South Korea
[5] Chungbuk Natl Univ, Coll Med, Dept Microbiol, Cheongju 361711, South Korea
关键词
Entecavir; Delayed type hypersensitivity; Maculopapular drug eruption; Dermatology; Adverse drug reaction; Chronic hepatitis B; BODY-WEIGHT; DRUG; LAMIVUDINE;
D O I
10.3748/wjg.v20.i42.15931
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Several clinical trials have demonstrated the potent antiviral efficacy of entecavir (ETV), and this relatively new nucleoside analogue drug has rapidly become a frequently prescribed therapy for chronic hepatitis B (CHB) worldwide. While the studies have also shown a good overall safety profile for ETV, adverse drug reactions (ADRs) in patients with advanced cirrhosis have been reported and represent a broad spectrum of drug-induced injuries, including lactic acidosis, myalgia, neuropathy, azotemia, hypophosphatemia, muscular weakness, and pancreatitis, as well as immune-mediated responses (i.e., allergic reactions). Cutaneous ADRs associated with ETV are very rare, with only two case reports in the publicly available literature; both of these cases were classified as unspecified hypersensitivity allergic (type I) ADR, but neither were reported as pathologically proven or as evaluated by cytokine release analysis. Here, we report the case of a 45-year-old woman who presented with a generalized maculopapular rash after one week of ETV treatment for lamivudine-resistant CHB. The patient reported having experienced a similar skin eruption during a previous three-month regimen of ETV, for which she had self-discontinued the medication. Histopathological analysis of a skin biopsy showed acanthotic epidermis with focal parakeratosis and a perivascular lymphocytic infiltrate admixed with interstitial eosinophils in the papillary and reticular dermis, consistent with a diagnosis of drug sensitivity. A lymphocyte stimulation test showed significantly enhanced IL-4, indicating a classification of type. IVb delayed hypersensitivity. The patient was switched to an adefovir-lamivudine combination regimen and the skin eruption resolved two weeks after the ETV withdrawal. This case represents the first pathologically and immunologically evidenced ETV-induced delayed type hypersensitivity skin reaction reported to date. Physicians should be aware of the potential, although rare, for cutaneous ADRs associated with ETV treatment. (C) 2014 Baishideng Publishing Group Inc. All rights reserved.
引用
收藏
页码:15931 / 15936
页数:6
相关论文
共 10 条
[1]   Super CitriMax (HCA-SX) attenuates increases in oxidative stress, inflammation, insulin resistance, and body weight in developing obese Zucker rats [J].
Asghar, Mohammad ;
Monjok, Emmanuel ;
Kouamou, Ghislaine ;
Ohia, Sunny E. ;
Bagchi, Debasis ;
Lokhandwala, Mustafa F. .
MOLECULAR AND CELLULAR BIOCHEMISTRY, 2007, 304 (1-2) :93-99
[2]   A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B [J].
Chang, TT ;
Gish, RG ;
de Man, R ;
Gadano, A ;
Sollano, J ;
Chao, YC ;
Lok, AS ;
Han, KH ;
Goodman, Z ;
Zhu, J ;
Cross, A ;
DeHertogh, D ;
Wilber, R ;
Colonno, R ;
Apelian, D .
NEW ENGLAND JOURNAL OF MEDICINE, 2006, 354 (10) :1001-1010
[3]   Cutaneous drug eruptions: A 5-year experience [J].
Gerson, Deborah ;
Sriganeshan, Vathany ;
Alexis, John B. .
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2008, 59 (06) :995-999
[4]   Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B [J].
Lai, CL ;
Shouval, D ;
Lok, AS ;
Chang, TT ;
Cheinquer, H ;
Goodman, Z ;
DeHertogh, D ;
Wilber, R ;
Zink, RC ;
Cross, A ;
Colonno, R ;
Fernandes, L .
NEW ENGLAND JOURNAL OF MEDICINE, 2006, 354 (10) :1011-1020
[5]   Long-term safety and tolerability of entecavir in patients with chronic hepatitis B in the rollover study ETV-901 [J].
Manns, Michael P. ;
Akarca, Ulus S. ;
Chang, Ting-Tsung ;
Sievert, William ;
Yoon, Seung Kew ;
Tsai, Naoky ;
Min, Albert ;
Pangerl, Andreas ;
Beebe, Suzanne ;
Yu, Miao ;
Wongcharatrawee, Suchat .
EXPERT OPINION ON DRUG SAFETY, 2012, 11 (03) :361-368
[6]   Cutaneous Drug Reactions in the Pediatric Population [J].
Noguera-Morel, Lucero ;
Hernandez-Martin, Angela ;
Torrelo, Antonio .
PEDIATRIC CLINICS OF NORTH AMERICA, 2014, 61 (02) :403-+
[7]   Dose- and time-dependent effects of a novel (-)-hydroxycitric acid extract on body weight, hepatic and testicular lipid peroxidation, DNA fragmentation and histopathological data over a period of 90 days [J].
Shara, M ;
Ohia, SE ;
Yasmin, T ;
Zardetto-Smith, A ;
Kincaid, A ;
Bagchi, M ;
Chatterjee, A ;
Bagchi, D ;
Stohs, SJ .
MOLECULAR AND CELLULAR BIOCHEMISTRY, 2003, 254 (1-2) :339-346
[8]   Immediate allergy, drug-induced eruption, by entecavir [J].
Sugiura, K. ;
Sugiura, M. ;
Takashi, T. ;
Naoki, H. ;
Itoh, A. .
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2009, 23 (04) :487-489
[9]   A whole blood in vitro cytokine release assay with aqueous monoclonal antibody presentation for the prediction of therapeutic protein induced cytokine release syndrome in humans [J].
Wolf, Babette ;
Morgan, Hannah ;
Krieg, Jennifer ;
Gani, Zaahira ;
Milicov, Adriana ;
Warncke, Max ;
Brennan, Frank ;
Jones, Stewart ;
Sims, Jennifer ;
Kiessling, Andrea .
CYTOKINE, 2012, 60 (03) :828-837
[10]   Maculopapular-type drug eruption caused by entecavir [J].
Yamada, Shigenori ;
Sawada, Yu ;
Nakamura, Motonobu .
EUROPEAN JOURNAL OF DERMATOLOGY, 2011, 21 (04) :635-636